Paclitaxel impairs mitochondrial dynamics in human sensory-like neuron cells.

Area of Science:

• Neuroscience
• Cell Biology
• Pharmacology

Background:

• Taxanes, like paclitaxel (PTX), are vital chemotherapy drugs for solid tumors.
• PTX frequently causes peripheral neuropathy, impacting 60-70% of patients.
• Mitochondrial dysfunction is linked to neuropathy, but the role of mitochondrial dynamics in sensory neurons is unclear.

Purpose of the Study:

• Investigate the impact of paclitaxel on mitochondrial plasticity in sensory neuron-like cells.
• Determine the role of mitochondrial fusion and fission processes in paclitaxel-induced neurotoxicity and pain signaling.

Main Methods:

• Incubated sensory neuron-like cells with paclitaxel.
• Analyzed changes in mitochondrial fusion (MFN1, MFN2) and fission (Drp1) proteins.
• Measured superoxide release, neuritogenesis, and pro-nociceptive signaling (ATF-3, substance P, PGE2).
• Tested the effect of a Drp1 inhibitor (P110) on paclitaxel-induced cytotoxicity.

Main Results:

• Paclitaxel induced mitochondrial fragmentation by altering MFN1/MFN2 and Drp1 levels.
• Paclitaxel increased superoxide release, impaired neuritogenesis, and activated pain signaling pathways.
• Inhibiting Drp1 with P110 protected cells from paclitaxel-induced cytotoxicity.

Conclusions:

• Paclitaxel neurotoxicity involves the impairment of mitochondrial dynamics in sensory neurons.
• Mitochondrial fragmentation and subsequent dysfunction contribute to paclitaxel-induced pain.
• Targeting mitochondrial fission presents a potential strategy to mitigate paclitaxel neurotoxicity and neuropathy.